TARA-002
Bacterial immunotherapy
Evidence outlook · registrational
Non-Muscle Invasive Bladder Cancer: registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2028-04.
Company guidance: regulatory filing expected second half of 2027 (Protara Therapeutics, 6 Nov 2026). “Based on engagement with the FDA under Breakthrough Therapy designation, the Company expects to initiate a rolling BLA submission for TARA-002 in the second half of 2027.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
ADVANCED-3 NCT07480356 · Non-Muscle Invasive Bladder Cancer Registry: NCT07480356 | 3 | Incidence of high-grade complete response (Month 6) 2028-04 | In progress: results expected 1 Apr 2028 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Non-Muscle Invasive Bladder Cancer: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TARA-002: this drug | Phase 3 | Bacterial immunotherapy | Innate and adaptive immune activation (inactivated Streptococcus pyogenes) | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Approved | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1501 | Phase 3 | Undisclosed | IL-15 | not yet graded | No reviewed efficacy summary in this indication | |
| TAR-210 | Phase 3 | Intravesical Drug Delivery System (erdafitinib) | — | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08052667 | Phase 1 | Antibody–drug conjugate | Integrin beta-6 (ITGB6) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow TARA-002 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.